MX2022009653A - Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b. - Google Patents

Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b.

Info

Publication number
MX2022009653A
MX2022009653A MX2022009653A MX2022009653A MX2022009653A MX 2022009653 A MX2022009653 A MX 2022009653A MX 2022009653 A MX2022009653 A MX 2022009653A MX 2022009653 A MX2022009653 A MX 2022009653A MX 2022009653 A MX2022009653 A MX 2022009653A
Authority
MX
Mexico
Prior art keywords
cell maturation
antigen
cells
receptors targeting
chimeric antigen
Prior art date
Application number
MX2022009653A
Other languages
English (en)
Inventor
James Noble Kochenderfer
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48045750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022009653(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health filed Critical Us Health
Publication of MX2022009653A publication Critical patent/MX2022009653A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona una secuencia de ácidos nucleicos aislada y purificada que codifica un receptor del antígeno quimérico (CAR), dirigido contra el Antígeno para la Maduración de las Células B (BCMA). La invención también proporciona células hospederas, tales como células T o células citotóxicas naturales (NK), que expresan el CAR y métodos para destruir las células del mieloma múltiple.
MX2022009653A 2012-04-11 2014-10-09 Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b. MX2022009653A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261622600P 2012-04-11 2012-04-11

Publications (1)

Publication Number Publication Date
MX2022009653A true MX2022009653A (es) 2022-09-07

Family

ID=48045750

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014012222A MX357823B (es) 2012-04-11 2013-03-15 Receptores del antígeno quimérico que seleccionan el antígeno para la maduración de las células b.
MX2018008352A MX2018008352A (es) 2012-04-11 2013-03-15 Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b.
MX2022009653A MX2022009653A (es) 2012-04-11 2014-10-09 Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2014012222A MX357823B (es) 2012-04-11 2013-03-15 Receptores del antígeno quimérico que seleccionan el antígeno para la maduración de las células b.
MX2018008352A MX2018008352A (es) 2012-04-11 2013-03-15 Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b.

Country Status (17)

Country Link
US (19) US9765342B2 (es)
EP (2) EP2836239A1 (es)
JP (5) JP6359520B2 (es)
KR (4) KR20220029757A (es)
CN (3) CN104379179A (es)
AU (4) AU2013246443B2 (es)
BR (1) BR112014024893B8 (es)
CA (1) CA2869562C (es)
EA (2) EA033110B1 (es)
HK (1) HK1203393A1 (es)
IL (4) IL234870B (es)
IS (1) IS9056A (es)
MX (3) MX357823B (es)
NZ (1) NZ700362A (es)
RU (2) RU2650805C2 (es)
SG (1) SG11201406414WA (es)
WO (1) WO2013154760A1 (es)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2650805C2 (ru) 2012-04-11 2018-04-17 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
AU2014265487B2 (en) 2013-05-14 2020-10-22 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (CAR) T-cells
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
TWI679976B (zh) 2013-11-13 2019-12-21 瑞士商諾華公司 低及免疫增強劑量之ｍｔｏｒ抑制劑及其用途
US10323077B2 (en) 2014-02-10 2019-06-18 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
JP6640726B2 (ja) 2014-02-14 2020-02-05 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム キメラ抗原受容体及びその製造方法
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
JP6556156B2 (ja) 2014-02-27 2019-08-07 ユーシーエル ビジネス ピーエルシー Ａｐｒｉｌバリアント
KR102157411B1 (ko) * 2014-03-19 2020-09-18 셀렉티스 암 면역요법을 위한 ｃｄ１２３ 특이적 키메라 항원 수용체들
AU2015243922B2 (en) 2014-04-10 2021-08-05 Seattle Children's Hospital (dba Seattle Children's Research Institute) Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection
CA2945620C (en) 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
SG10201808258SA (en) * 2014-04-25 2018-10-30 Bluebird Bio Inc Improved methods for manufacturing adoptive cell therapies
PT3134432T (pt) 2014-04-25 2020-04-01 Bluebird Bio Inc Recetores do antígeno quimérico do promotor mnd
US10301370B2 (en) 2014-05-02 2019-05-28 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor T cells
JP6797693B2 (ja) * 2014-06-02 2020-12-09 アメリカ合衆国 Ｃｄ−１９を標的とするキメラ抗原受容体
EP3828265A1 (en) * 2014-06-06 2021-06-02 Bluebird Bio, Inc. Improved t cell compositions
ES2813437T3 (es) * 2014-07-11 2021-03-23 Celgene Corp Métodos para mejorar la eficiencia de la transducción vectorial en linfocitos T
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
CA2955386A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014535A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
US20170226216A1 (en) 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
MX367787B (es) * 2014-07-29 2019-09-06 Cellectis Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3189148A4 (en) 2014-09-02 2018-05-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
BR112017011914A2 (pt) 2014-12-05 2018-02-27 Memorial Sloan-Kettering Cancer Center ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso?
CN113603795A (zh) * 2014-12-05 2021-11-05 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
CN112358551B (zh) * 2014-12-12 2024-02-02 2赛文缇生物公司 Bcma嵌合抗原受体
BR112017013176A2 (pt) * 2014-12-19 2018-05-15 Dana Farber Cancer Inst Inc receptores de antígenos quiméricos e métodos para usá-los
JP6768664B2 (ja) 2014-12-24 2020-10-14 アーディジェン， エルエルシー 分子の細胞内送達のためのペプチドおよびナノ粒子
BR112017014547A2 (pt) 2015-01-26 2018-01-16 Cellectis sistemas de receptor de antígeno quimérico dirigidos por mab para classificação/depleção de células imunes engenheiradas
CN107614008A (zh) * 2015-03-20 2018-01-19 蓝鸟生物公司 载体制剂
US11136401B2 (en) 2015-03-27 2021-10-05 University Of Southern California Car t-cell therapy directed to LHR for the treatment of solid tumors
BR112017019914A2 (pt) * 2015-04-13 2018-06-19 Pfizer receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b
AU2016248946B2 (en) 2015-04-13 2022-03-10 Pfizer Inc. Therapeutic antibodies and their uses
US20180117155A1 (en) 2015-04-25 2018-05-03 The General Hospital Corporation Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
JP2018515123A (ja) 2015-05-18 2018-06-14 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
AU2016263176A1 (en) 2015-05-20 2017-12-07 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
CN107847601A (zh) * 2015-06-04 2018-03-27 南加利福尼亚大学 Lym‑1和lym‑2靶向的car细胞免疫疗法
WO2016201300A1 (en) * 2015-06-12 2016-12-15 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
PL3310805T3 (pl) 2015-06-19 2021-08-23 Sebastian KOBOLD Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynie
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
ES2777602T3 (es) * 2015-08-03 2020-08-05 Engmab Sàrl Anticuerpos monoclonales contra el antígeno de maduración de células b humanas (BCMA)
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP7010487B2 (ja) 2015-08-17 2022-03-03 ソウル大学校産学協力団 抗コチニン抗体が連結したキメラ抗原受容体およびその使用
CN108348606A (zh) 2015-09-18 2018-07-31 综合医院公司以麻省总医院名义经营 用于治疗癌症的抗趋除剂的局部递送
WO2017064222A1 (en) 2015-10-16 2017-04-20 Ludwig-Maximilians-Universität München Cxcr6-transduced t cells for targeted tumor therapy
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
CN108473575B (zh) 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
GB2561755A (en) * 2015-11-26 2018-10-24 Guangzhou Cas Lamvac Biotech Co Ltd Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
EP3708588A1 (en) 2015-11-27 2020-09-16 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research INTERFERON CANCER TREATMENT METHODS
US11090334B2 (en) 2016-01-29 2021-08-17 Med Manor Organics (P) Ltd. Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
CN109641008B (zh) 2016-04-01 2021-03-23 凯德药业股份有限公司 嵌合受体及其方法和用途
CU20180121A7 (es) 2016-04-01 2019-05-03 Kite Pharma Inc Receptores de antígenos quiméricos y células t
CA3019135A1 (en) 2016-04-01 2017-10-05 Kite Pharma, Inc. Bcma binding molecules and methods of use thereof
WO2017205747A1 (en) 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
AU2017276706A1 (en) * 2016-06-07 2019-01-03 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
US11547748B2 (en) 2016-06-30 2023-01-10 Hoffmann-La Roche Inc. Adoptive t-cell therapy
CN109715668A (zh) 2016-08-02 2019-05-03 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
KR20190046854A (ko) * 2016-09-14 2019-05-07 얀센 바이오테크 인코포레이티드 Bcma-특이적 피브로넥틴 iii 형 도메인을 포함하는 키메라 항원 수용체 및 그의 용도
EP3445787B1 (en) 2016-10-07 2020-12-02 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
CN108004259B (zh) * 2016-11-02 2020-06-30 上海恒润达生生物科技有限公司 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018096402A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
EP3548048A4 (en) * 2016-12-02 2020-07-01 Cartesian Therapeutics, Inc. CANCER IMMUNOTHERAPY WITH CD8 + HIGHLY ENRICHED CHIMERIC ANTIGEN RECEPTOR T CELLS
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
CN110475857B (zh) 2017-01-05 2023-07-18 韩国生命工学研究院 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
MX2019011324A (es) 2017-03-23 2020-01-21 Massachusetts Gen Hospital Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
CA3058425A1 (en) * 2017-03-28 2018-10-04 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
US20200101108A1 (en) 2017-03-31 2020-04-02 The Board Of Trustees Of The Le-Land Standford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
KR20240059648A (ko) 2017-04-19 2024-05-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018204427A1 (en) 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US20180325955A1 (en) 2017-05-12 2018-11-15 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
IL271194B1 (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
IL271597B2 (en) * 2017-06-30 2024-03-01 Us Health Chimeric antigen receptors for anti-maturation B-cell antigen with human domains
CN117018219A (zh) 2017-08-01 2023-11-10 免疫医疗有限责任公司 Bcma单克隆抗体-药物缀合物
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
WO2019053613A2 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
CN111107874A (zh) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
JP2020535128A (ja) 2017-09-19 2020-12-03 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
MX2020004013A (es) 2017-10-18 2021-01-08 Novartis Ag Composiciones y metodos para la degradacion selectiva de proteinas.
MA50860A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
CN109748968B (zh) * 2017-11-03 2020-12-01 西安宇繁生物科技有限责任公司 Bcma特异性嵌合抗原受体t细胞及其应用
JP7233425B2 (ja) 2017-11-06 2023-03-06 ジュノー セラピューティクス インコーポレイテッド 細胞療法とガンマセクレターゼ阻害剤との組み合わせ
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
MX2020006689A (es) * 2017-12-20 2020-11-06 Poseida Therapeutics Inc Composiciones de vcar y metodos de uso.
CN109971715A (zh) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 一种扩增特异性car-t细胞的培养方法
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
TW201940182A (zh) 2018-01-22 2019-10-16 美商安德賽特公司 Car t 細胞之使用方法
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019149249A1 (zh) * 2018-02-01 2019-08-08 南京驯鹿医疗技术有限公司 一种结合bcma的嵌合抗原受体(car)及其应用
CN110662771B (zh) * 2018-02-01 2023-07-28 南京驯鹿生物技术股份有限公司 一种结合bcma的嵌合抗原受体(car)及其应用
CN111868246A (zh) 2018-02-09 2020-10-30 美国卫生和人力服务部 拴系白细胞介素-15和白细胞介素-21
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110157675B (zh) * 2018-02-12 2022-05-27 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
CN116836297A (zh) 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
WO2019209715A1 (en) 2018-04-24 2019-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
CN112203725A (zh) * 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途
CN112714769A (zh) * 2018-07-10 2021-04-27 普瑞赛格恩公司 Ror-1特异性嵌合抗原受体及其用途
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
BR112021003305A2 (pt) 2018-08-31 2021-05-25 Novartis Ag métodos para produzir células que expressam receptor de antígeno quimérico
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
WO2020089794A1 (en) 2018-10-31 2020-05-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
EP3873937A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
JP7386382B2 (ja) 2018-12-12 2023-11-27 カイト ファーマ インコーポレイテッド キメラ抗原受容体及びｔ細胞受容体並びに使用方法
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
CN112074279B (zh) * 2019-01-16 2024-01-26 卡里布生物科学公司 人源化bcma抗体和bcma-car-t细胞
CN113710703A (zh) 2019-02-15 2021-11-26 南加利福尼亚大学 Lym-1和lym-2抗体组合物及改进的car构建体
SG11202107825WA (en) 2019-02-25 2021-09-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
MX2021010288A (es) 2019-03-01 2021-09-23 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
US20220143087A1 (en) 2019-03-08 2022-05-12 Klinikum Der Universitat Munchen Ccr8 expressing lymphocytes for targeted tumor therapy
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
JP7379654B2 (ja) * 2019-03-15 2023-11-14 カーティザン セラピューティクス，インコーポレーテッド 抗ｂｃｍａキメラ抗原受容体
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
JP2022529618A (ja) 2019-04-04 2022-06-23 上海医薬集団股▲フン▼有限公司 腫瘍抗原認識受容体を有する免疫細胞とその応用
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
EA202192975A1 (ru) 2019-04-30 2022-02-01 Криспр Терапьютикс Аг Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19
EP3733707A1 (en) 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
KR20220017914A (ko) 2019-05-07 2022-02-14 그라셀 바이오테크놀로지스 (상하이) 컴퍼니, 리미티드 Bcma를 표적으로 하는 조작된 면역 세포 및 그의 용도
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
CN112585168B (zh) 2019-07-30 2022-04-15 上海翰森生物医药科技有限公司 抗bcma抗体、其抗原结合片段及其医药用途
AU2020325753A1 (en) 2019-08-06 2022-03-03 Glaxosmithkline Intellectual Property Development Limited Biopharmacuetical compositions and related methods
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
KR20220041934A (ko) 2019-08-16 2022-04-01 얀센 바이오테크 인코포레이티드 개선된 기능을 갖는 치료용 면역 세포 및 이의 제조 방법
CN112409482B (zh) * 2019-08-20 2022-08-26 杭州尚健生物技术有限公司 Bcma抗体
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
CN114729046A (zh) * 2019-09-18 2022-07-08 得克萨斯大学体系董事会 工程化自然杀伤细胞以靶向bcma阳性肿瘤的方法
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
CN110642953B (zh) * 2019-10-12 2021-09-17 华夏源（上海）细胞基因工程股份有限公司 一种靶向bcma的t细胞受体融合蛋白和应用
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
EP4065158A2 (en) 2019-11-26 2022-10-05 Novartis AG Chimeric antigen receptors binding bcma and cd19 and uses thereof
WO2021132746A1 (en) * 2019-12-24 2021-07-01 Abl Bio, Inc. Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
JP2023512452A (ja) * 2020-01-13 2023-03-27 ンカルタ・インコーポレイテッド Ｂｃｍａ指向性細胞免疫療法組成物および方法
MX2022010685A (es) 2020-02-27 2022-09-23 Novartis Ag Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
JP2023516008A (ja) 2020-02-27 2023-04-17 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
KR20220166282A (ko) 2020-03-10 2022-12-16 매사추세츠 인스티튜트 오브 테크놀로지 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
IL296241A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Compositions and methods for immunotherapy for npm1c-positive cancer
KR102371151B1 (ko) * 2020-03-13 2022-03-07 주식회사 큐로셀 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물
WO2021222330A2 (en) 2020-04-28 2021-11-04 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
KR102400977B1 (ko) 2020-05-29 2022-05-25 성균관대학교산학협력단 프로세서를 통한 페이지 폴트 처리 방법
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
EP4192875A1 (en) * 2020-08-10 2023-06-14 Precision BioSciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
TW202227124A (zh) 2020-08-21 2022-07-16 瑞士商諾華公司 用於體內產生ｃａｒ表現細胞的組成物和方法
CN116583537A (zh) 2020-09-08 2023-08-11 美国卫生和人力服务部 与对过继细胞疗法的应答相关的t细胞表型
US20230399412A1 (en) 2020-10-12 2023-12-14 Nanjing IASO Biotechnology Co., Ltd. Antibody and chimeric antigen receptor (car) binding to cd70, and application thereof
CN116568709A (zh) 2020-11-01 2023-08-08 南京驯鹿生物技术股份有限公司 靶向cd5的全人源抗体、全人源嵌合抗原受体（car）及其应用
US20240018210A1 (en) 2020-11-13 2024-01-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
EP4257617A1 (en) 2020-12-01 2023-10-11 Cure Genetics Co., Ltd Antigen-binding protein targeting cd70 and use thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
CN113087798B (zh) * 2020-12-31 2022-05-24 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
US20240050568A1 (en) 2021-01-12 2024-02-15 Nanjing IASO Biotechnology Co., Ltd. Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof
KR20230165771A (ko) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 dgk 억제제의 조합
IL307612A (en) 2021-04-16 2023-12-01 Celgene Corp Combined therapies with BCMA-directed T-cell therapy
EP4322991A1 (en) 2021-04-16 2024-02-21 Celgene Corporation T cell therapy in patients who have had prior stem cell transplant
EP4330381A1 (en) 2021-04-27 2024-03-06 Novartis AG Viral vector production system
EP4334341A2 (en) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Methods for stimulating and transducing t cells
JP2024521187A (ja) 2021-05-28 2024-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ガンの治療のための組み合わせ療法
CN117794954A (zh) 2021-08-03 2024-03-29 葛兰素史密斯克莱知识产权发展有限公司 生物药物组合物和稳定同位素标记肽图谱方法
EP4384598A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
AU2022326565A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
IL310691A (en) 2021-08-11 2024-04-01 Sana Biotechnology Inc Genetically modified primary cells for allogeneic cell therapy
WO2023021113A1 (en) 2021-08-18 2023-02-23 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
TW202323521A (zh) 2021-08-20 2023-06-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
WO2023025208A1 (zh) 2021-08-24 2023-03-02 赛斯尔擎生物技术（上海）有限公司 一种修饰细胞的方法
CN117858943A (zh) 2021-08-24 2024-04-09 赛斯尔擎生物技术（上海）有限公司 T细胞产品及其用途
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
CN114015674A (zh) 2021-11-02 2022-02-08 辉二(上海)生物科技有限公司 新型CRISPR-Cas12i系统
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
WO2023079494A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
TW202334400A (zh) 2021-12-30 2023-09-01 美商Ｔｒ１Ｘ股份有限公司 表現il-10及嵌合抗原受體之cd4+ t細胞及其用途
WO2023130040A2 (en) 2021-12-31 2023-07-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell therapy with vaccination as a combination immunotherapy against cancer
WO2023144702A1 (en) 2022-01-25 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Combination therapy for cancer
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024097311A2 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Hypoimmunogenic mail cells, methods of making and methods of using same
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024121711A1 (en) 2022-12-05 2024-06-13 Glaxosmithkline Intellectual Property Development Limited Methods of treatment using b-cell maturation antigen antagonists
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
AU2005200008B2 (en) * 1999-01-07 2008-03-06 Zymogenetics, Inc. Soluble receptor BR43x2 and methods of using
GB0013345D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Modified receptor and assay
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
BRPI0411526A (pt) 2003-06-18 2006-08-01 Genelux Corp vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
LT2311874T (lt) 2004-07-22 2017-11-27 Erasmus University Medical Center Rotterdam Rišančiosios molekulės
KR20080025066A (ko) 2005-05-18 2008-03-19 바이오겐 아이덱 인크. 섬유성 상태의 치료 방법
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
ES2523033T3 (es) * 2008-03-18 2014-11-20 Seattle Genetics, Inc. Conjugados enlazadores del fármaco auriestatina
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2010104949A2 (en) * 2009-03-10 2010-09-16 Biogen Idec Ma Inc. Anti-bcma antibodies
EP2483301A1 (en) * 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
RU2444570C1 (ru) * 2010-06-23 2012-03-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф.Гамалеи" Министерства здравоохранения и социального развития Российской Федерации Способ получения рекомбинантной вакцины
EP2614077B1 (en) * 2010-09-08 2016-08-17 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
EP2614151B1 (en) 2010-09-08 2019-07-24 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
US9499629B2 (en) * 2010-12-09 2016-11-22 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified T-cells to treat cancer
CN106279418A (zh) 2011-05-27 2017-01-04 葛兰素集团有限公司 Bcma（cd269/tnfrsf17）结合蛋白
WO2013123061A1 (en) 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
ES2816450T3 (es) * 2012-02-22 2021-04-05 Univ Pennsylvania Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR
RU2650805C2 (ru) * 2012-04-11 2018-04-17 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
CN108473575B (zh) 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
EP3565830B1 (en) 2017-01-09 2021-03-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
IL271597B2 (en) 2017-06-30 2024-03-01 Us Health Chimeric antigen receptors for anti-maturation B-cell antigen with human domains

Also Published As

Publication number Publication date
CN110295186A (zh) 2019-10-01
US20200087670A1 (en) 2020-03-19
JP2015513920A (ja) 2015-05-18
CN104379179A (zh) 2015-02-25
RU2018111462A (ru) 2019-02-27
JP6359520B2 (ja) 2018-07-18
IL234870B (en) 2020-06-30
AU2021202158A1 (en) 2021-05-06
NZ700362A (en) 2016-09-30
JP6989634B2 (ja) 2022-01-05
IL290471A (en) 2022-04-01
CN110331154A (zh) 2019-10-15
KR20210032014A (ko) 2021-03-23
US10900042B2 (en) 2021-01-26
BR112014024893B8 (pt) 2022-09-06
US10829769B2 (en) 2020-11-10
US10829768B2 (en) 2020-11-10
SG11201406414WA (en) 2014-11-27
EP2836239A1 (en) 2015-02-18
MX357823B (es) 2018-07-25
US11377660B2 (en) 2022-07-05
US11827889B2 (en) 2023-11-28
US10876123B2 (en) 2020-12-29
IL263417A (en) 2018-12-31
US20200087667A1 (en) 2020-03-19
RU2014144143A (ru) 2016-06-10
US10738313B2 (en) 2020-08-11
US11773396B2 (en) 2023-10-03
RU2018111462A3 (es) 2021-07-27
AU2013246443B2 (en) 2017-04-27
AU2017208279A1 (en) 2017-08-10
US9765342B2 (en) 2017-09-19
US20210095294A1 (en) 2021-04-01
KR20150003306A (ko) 2015-01-08
US20200087669A1 (en) 2020-03-19
RU2766608C2 (ru) 2022-03-15
EA201990959A1 (ru) 2020-02-10
US10815488B2 (en) 2020-10-27
KR102086874B1 (ko) 2020-03-10
US20180051292A1 (en) 2018-02-22
CA2869562A1 (en) 2013-10-17
MX2014012222A (es) 2014-11-25
US20200071708A1 (en) 2020-03-05
KR20200027047A (ko) 2020-03-11
US20230002776A1 (en) 2023-01-05
US20200071705A1 (en) 2020-03-05
US20210123063A1 (en) 2021-04-29
AU2013246443A1 (en) 2014-10-23
IL278003A (en) 2020-11-30
US20210095295A1 (en) 2021-04-01
AU2019203042B2 (en) 2021-03-11
US20150051266A1 (en) 2015-02-19
US20200071710A1 (en) 2020-03-05
MX2018008352A (es) 2022-08-10
BR112014024893A2 (pt) 2017-07-11
JP2020078322A (ja) 2020-05-28
EA201491837A1 (ru) 2015-03-31
US10844387B2 (en) 2020-11-24
US10767184B2 (en) 2020-09-08
US20200071706A1 (en) 2020-03-05
US10837019B2 (en) 2020-11-17
US10738312B2 (en) 2020-08-11
US10815487B2 (en) 2020-10-27
US20200102567A1 (en) 2020-04-02
IL263417B (en) 2020-10-29
RU2650805C2 (ru) 2018-04-17
US10829767B2 (en) 2020-11-10
KR102229945B1 (ko) 2021-03-18
JP2023175763A (ja) 2023-12-12
JP6657317B2 (ja) 2020-03-04
HK1203393A1 (en) 2015-10-30
US11359204B2 (en) 2022-06-14
US20200071709A1 (en) 2020-03-05
KR20220029757A (ko) 2022-03-08
AU2019203042A1 (en) 2019-05-23
BR112014024893B1 (pt) 2021-03-30
JP2022058345A (ja) 2022-04-12
CA2869562C (en) 2023-09-12
EA033110B1 (ru) 2019-08-30
US20200071707A1 (en) 2020-03-05
WO2013154760A1 (en) 2013-10-17
US20230030998A1 (en) 2023-02-02
US20200087668A1 (en) 2020-03-19
AU2017208279B2 (en) 2019-03-07
EP3689383A1 (en) 2020-08-05
IS9056A (is) 2014-10-06
JP2018161140A (ja) 2018-10-18
US11066674B2 (en) 2021-07-20
US20230050416A1 (en) 2023-02-16
IL234870A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
MX2022009653A (es) Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b.
MX2021007011A (es) Receptores de antigenos quimericos de antigeno de maduracion de celulas b.
IL280576B (en) Chimeric antigen receptor T cells target il13ra2
MX2021006239A (es) Receptores quimericos de antigeno que tienen como diana a cd-19.
SA517381666B1 (ar) B مستقبلات مولد ضد خيمري تستهدف مولد ضد نضج الخلايا
EP3665271A4 (en) CELL TARGETING MEDIA BY A CHEMICAL ANTIGEN RECEPTOR
MX2017001079A (es) Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
PH12017501044A1 (en) Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MY180714A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
JO3755B1 (ar) تركيبات تستوستيرون
MX2017005661A (es) Celulas de mamifero que expresan antigenos de citomegalovirus.
MX2018004289A (es) Receptores de antigenos quimericos dirigidos a psca.
GB201017519D0 (en) Vaccines
IN2014DN07984A (es)
IN2014DN07983A (es)
IL212511A0 (en) System and method for keyword spotting using multiple character encoding schemes
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.